₹37.70
−3.58%NSE close, 16 Nov 2026
−21.87%
ONYX BIOTEC is a small cap company, listed on NSE SME under the symbol ONYX. At ₹37.70 a share, the market values the whole company at ₹68 crore. NSE SME is the exchange's platform for small and medium companies, which report their results every half year.
In FY26, it reported sales of ₹69 crore and a net loss of ₹0 crore, an operating margin of 4.9%.
The market values the company at 41.9 times its profit over the last twelve months and 1.21 times its book value; its return on equity is 2.9% and its borrowings are 0.19 times its equity.
Promoters hold 41.74% of the shares. Foreign institutions hold 0.22%, and domestic institutions, mutual funds among them, 2.39%.
Over the past year the share price has fallen 3.3%, and it is 24.1% below its 52-week high.
Listed on NSE SME, the platform for small and medium companies: its shares trade in large lots and often thinly, so the price can move sharply on a few trades, and companies file results every half year.
₹ crore. Standalone figures: the company files no consolidated results.
| Line | Sep 2024 | 6M to Mar 2025 | 6M to Sep 2025 | 6M to Mar 2026 | 6M to Sep 2026 |
|---|---|---|---|---|---|
| Sales | 30.2 | 31.8 | 34.6 | 34.9 | 43.4 |
| Expenses | 24.4 | 27.2 | 33.7 | 32.4 |
The financial results for the period ended September 30, 2026.
A copy of corrigendum to the letter of offer for the attention to the public shareholders of the Onyx Biotec Limited.
A copy of offer opening public announcement cum corrigendum to the detailed public statement to the public shareholders of the Onyx Biotec Limited (Target Company).
Has informed regarding Submission of the Non-Applicability of the provisions relating to Corporate Governance as specified in the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
| 40.6 |
| Operating profit | 5.7 | 4.6 | 0.9 | 2.5 | 2.9 |
|---|
| Operating margin | 18.9% | 14.6% | 2.7% | 7.0% | 6.6% |
|---|
| Other income | 1.0 | 0.2 | 0.2 | 0.2 | 0.4 |
|---|
| Interest | 1.4 | 0.6 | 0.6 | 0.7 | 0.6 |
|---|
| Depreciation | 1.5 | 1.5 | 1.6 | 1.5 | 1.5 |
|---|
| Profit before tax | 3.8 | 2.7 | −0.9 | 0.5 | 1.3 |
|---|
| Tax | 0.8 | 0.7 | −0.0 | −0.2 | 0.3 |
|---|
| Net profit | 3.0 | 2.0 | −0.9 | 0.7 | 0.9 |
|---|
| EPS (₹) | 2.24 | 1.31 | -0.50 | 0.38 | 0.52 |
|---|
₹ crore, financial years to March.
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|
| From operations | 1.4 | −1.5 | 3.3 |
| From investing | 0.7 | −4.6 | −1.3 |
| From financing | 5.1 | 1.5 | −4.9 |
| Spent on fixed assets | −1.1 | −5.0 | −1.3 |
| Free cash flow | 0.4 | −6.5 | 2.0 |
Margins, returns, debt, tax and cash.
| Line | FY25 | FY26 |
|---|---|---|
| Net margin | 8.0% | -0.3% |
| Operating margin | 16.7% | 4.9% |
| Return on equity | 8.9% | -0.4% |
| Return on capital employed | 12.4% | 1.1% |
| Return on assets | 5.4% | -0.2% |
| Debt to equity | 0.22 | 0.27 |
| Interest coverage | 4.30 | 0.70 |
| Debt to assets | 0.14 | 0.16 |
| Current ratio | 1.91 | 1.58 |
| Quick ratio | 1.29 | 1.14 |
| Cash ratio | 0.33 | 0.12 |
| Asset turnover | 0.68 | 0.73 |
| Fixed asset turnover | 1.51 | 1.77 |
| Inventory turnover | 2.40 | 3.70 |
| Receivables turnover | 3.10 | 2.50 |
| Gross margin | 36.8% | 25.7% |
| Cash from operations to profit | 29.0% | – |
| Effective tax rate | 23.5% | – |
A newspaper copy of the Recommendation of the Independent Director Committee ("IDC") of the company in relation to the Open Offer made by Mr. Kunal Bhardwaj ( Acquirer 1 ), Mr. Gautam Bhardwaj ( Acquirer 2 ), Mr. Kanhaiya Bhardwaj ( Acquirer 3 ) and Mr. Kapil Bhardwaj (…
The outcome of the meeting of the committee of the Independent Directors held today i.e. October 07, 2026 to give their recomendation in the Open Offer of Onyx Biotec Limited in compliance with Regulation 26(7) of the SEBI (SAST) Regulations, 2011and subsequent Amendments…
A copy of Letter of Offer.
A copy Srutinizers report of Annual General Meeting held on September 28, 2026. Further, the company has informed the Exchange regarding voting results.
Proceedings of Annual General Meeting held on September 28, 2026
Notice of Annual General Meeting to be held on September 28, 2026
Outcome of Board Meeting held on September 03, 2026.
A copy of corrigendum to the public announcement dated July24, 2026 for the attention of the public shareholders of the Onyx Biotec Limited.
A copy of Detailed public statement in terms of Regulations 3(1) & 4 Read with Regulation 15(2) of the SEBI (SAST) Regulations, 2011, as amended for the attention of the Public shareholders of the company.
A copy of Public announcement under Regulations 3(1) and 4 Read with Regulations 13, 14 and 15 of the SEBI (SAST) Regulations, 2011 ("SEBI SAST Regulations") for the attention of the Equity shareholders of the company.